© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Benzoylmetronidazole came into focus as researchers in the mid-twentieth century dug deeper into nitroimidazole chemistry. The search for modifications that overcame certain pharmacological hurdles of foundational molecules like metronidazole led to the emergence of benzoyl-derivatives. Chemists saw early on that adding a benzoyl group could shift the pharmacodynamics of these drugs, possibly providing new angles on fighting infections. By the 1970s, teams in Eastern Europe and China began patenting and publishing methods to synthesize such compounds, hoping to improve drug stability, decrease undesired side effects, and tackle resistance mechanisms that were cropping up in sensitive microbial populations. This wasn’t just tinkering at the margins—benzoylmetronidazole represented an entire concept shift about how to use functional group chemistry to open up more possibilities for where and how nitroimidazole family drugs could be used.
Benzoylmetronidazole is essentially a prodrug: it takes the core structure of metronidazole, then swaps one of its hydrogen atoms for a benzoyl group. On the shelf or under a microscope, it presents a white or nearly white powder. This adjustment may look minor on paper, but it shifts the absorption, distribution, and sometimes how a body handles the metabolic breakdown. In simple terms, it isn’t just a tweak—it’s a real transformation of both the drug’s reach and its safety margins. People working on formulation or compounding know that minor chemical differences can make the difference between a medicine that works only in the gut versus one that can be delivered in more controlled-release systems.
This compound tips the scales in its powder form at a molecular weight higher than plain metronidazole, thanks to the benzoyl ring. It boasts a melting point in the range of 157°C to 161°C, signaling sturdy intermolecular forces and solid shelf stability under most pharmaceutical storage situations. On the solubility front, it fares better in organic solvents like ethanol or chloroform than it does in water. The pH doesn’t cause wild swings in its behavior, which matters for oral dosage forms that need to pass through acidic stomach environments. Its chemical formula, C13H13N3O4, tells its own story about added complexity. Experience shows that this kind of modification often means improved masking of bitter taste in oral suspensions—something any pharmacist will admit helps drumming up patient compliance.
Industry guidelines suggest a purity that tops 99% by HPLC analysis, limiting impurities like residual solvents and unreacted starting materials. Batch certificates clarify that heavy metals sit below the strictest legal thresholds, and most suppliers pinpoint benzoylmetronidazole’s identity with a combination of melting point, IR spectra, and chromatographic fingerprinting. For packaging, light-resistant containers with desiccant pouches see wide use in bulk supply chains, cutting down on hydrolysis or photodegradation risks. Pharmaceutical producers must spell out storage directions, batch identification, detailed expiration dates, and all major regulatory compliance badges directly on external labels, building trust with purchasing managers and hospital pharmacies who bear the legal and ethical responsibility for safe drugs.
Making benzoylmetronidazole means starting with metronidazole itself—already a staple in the lab. Through an acylation reaction, benzoyl chloride gets introduced under basic conditions, perhaps using pyridine as solvent or catalyst. As the reagents swirl together, the benzoyl group latches onto the nitrogen atom of the nitroimidazole ring. The process demands close attention to temperature control, since overheating invites unwanted side products that throw off yields and muddy the purification downstream. Post-reaction, a series of washes with water and possibly organic solvents like ethyl acetate remove excess reactants and byproducts. Several rounds of recrystallization follow before the final compound passes muster for purity and performance. Those with hands-on experience know the difference a few degrees or a slight solvent tweak can make when chasing both high yields and a product that passes rigorous quality checks.
Benzoylmetronidazole holds potential for further chemistry beyond the initial synthesis. Under hydrolytic conditions, the benzoyl group cleaves off, yielding back the original metronidazole—a reversible modification that highlights how this prodrug acts as a masked version. Exposure to strong acids or bases speeds that process along, a useful trick for designing targeted-release oral drug forms that exploit pH differences across the body. Some chemists tested further acylations or the introduction of electron-withdrawing substituents at the benzoyl ring, with hopes of fine-tuning properties like lipophilicity or the speed at which the drug “unmasks” in the bloodstream. Others have attached polymers or nanocarrier systems to this structure, exploring delivery platforms that improve tissue penetration or reduce dosing frequency.
In chemical registries, benzoylmetronidazole carries synonyms such as 1-(2-Hydroxyethyl)-2-methyl-5-nitroimidazolium benzoylate and BMZ in shorthand. Public records from the early patent filings sometimes list it as metronidazole benzoate. For industry catalogues, its CAS number brings order to potential mix-ups, while some formulations earmark it as Benmet or Benzomet. Each name signals its own context: the scientific community grabs onto whatever label fits their need, whether it’s compliance documents, reagent orders, or clinical trial reports.
Work with benzoylmetronidazole adheres to established personal protective standards: gloves, goggles, and ventilated laboratory hoods. Safety data sheets outline that accidental inhalation or skin contact brings moderate irritation risk, and chronic exposure could carry the same nitroimidazole-linked reproductive or mutagenic concerns flagged for metronidazole. Storage apart from acids and bases, in dry, cool places, cuts down on hydrolytic breakdown. Waste disposal must channel spent material through monitored hazardous waste streams, with special attention to preventing contamination of water sources. On the production side, occupational health managers stay vigilant, reinforcing spill response protocols and regular air quality checks.
Benzoylmetronidazole’s calling card lies in its performance as a prodrug within medicine. Once in the digestive tract, enzymes or pH-triggered hydrolysis deliver the active metronidazole into the bloodstream. This feature often solves the problem of poor palatability in pediatric or veterinary formulations, shifting a drug’s marketability from theoretical to practical. Some dental preparations tap into its stability for use as topical antimicrobial gels or pastes, providing alternatives to standard nitroimidazole gels that don’t store as well in humid climates. Research into treating protozoal infections—or sparring with anaerobic bacterial pathogens—leverages its profile to widen options for patients who show allergic responses or intolerance to standard therapies. In the lab, its chemistry offers a testing ground for further tweaking prodrug strategies.
Scientists keep searching for new tricks with benzoylmetronidazole. Researchers in pharmacokinetics test blood levels and monitor metabolic pathways after administration, seeking the magic blend of quick release and enduring therapeutic windows. Formulation teams compare traditional tablets, dispersible powders, and slow-release pearls to gauge where the compound delivers its best profile. In infectious disease labs, microbiologists challenge emerging drug-resistant strains with benzoylmetronidazole, hoping to block resistance mechanisms or at least buy time against superbugs. Teams in veterinary medicine, especially in livestock and companion animal fields, value the molecule’s shelf stability when medicines move long distances through supply chains that don't always guarantee refrigeration or humidity control.
Any new compound earns its stripes in the toxicology department. Benzoylmetronidazole’s breakdown products mirror those of metronidazole, raising similar concerns about liver metabolism and possible mutagenicity with extended use. Preclinical studies in rodents and rabbits track markers of acute toxicity, organ weight changes, and reproductive health over repeated doses. In cell cultures, geneticists test for chromosomal aberrations or increased rates of cancerous transformations after dosing. Regulatory agencies push for post-market monitoring of adverse events, gathering data that fills in the picture beyond what animal models or computer predictions can provide. In practice, clinicians look out for rare hypersensitivity reactions, interactions with other drugs—especially those metabolized in the liver—and advise patients on the importance of completing treatment to minimize both resistance development and the chance of lingering side effects.
Benzoylmetronidazole’s pathway stretches ahead as part of a broader pattern of rethinking old drugs for new purposes. With antimicrobial resistance growing, revisiting the chemistry of trusted compounds, using strategies like prodrug masking, gives medicine another angle of attack. Collaborative efforts among synthetic chemists, formulation experts, and clinicians stand the best chance of unlocking fresh value—not just as new treatments, but potentially as stepping stones to more complex delivery technologies. As global supply chains shift, and registration demands tighten, only those compounds that balance reliability, safety, and manufacturing practicality can hope for real uptake in both established and emerging markets. Benzoylmetronidazole’s experience shows that sometimes the smart move isn’t chasing exotic new molecules, but giving old ideas a sharper edge and a broader reach.
Benzoylmetronidazole doesn’t show up in everyday conversations about medicine, but it plays a useful role for many people dealing with certain infections. As a derivative of metronidazole, it steps in most often for intestinal and gynecological infections caused by anaerobic bacteria and protozoa. These are the types of nasty bugs that thrive where oxygen barely reaches the tissue, creating stubborn and sometimes recurrent problems. Doctors and pharmacists don’t pick a medication like this lightly; they reach for it when they want something targeted, effective, and well-researched.
When my relatives struggled with stubborn gut infections, a doctor recommended treatments containing metronidazole derivatives. Benzoylmetronidazole belongs in this family. The metabolism in the body turns it into the active component that seeks out DNA of the problem-causing microbes. By disrupting DNA within bacteria and protozoa, it stops these invaders from growing and spreading. I’ve seen firsthand how important it feels to take a medication that not only holds promise in the lab, but delivers real results at home—helping people get back to daily routines without lingering pain or fatigue from infection.
Clinics in cities and rural towns alike run into patients with infections from amoebas or trichomonas. Resistance to common drugs sometimes muddies the water, so healthcare workers appreciate having alternatives. Reports highlight how Benzoylmetronidazole’s specialty comes in as an oral agent; it’s convenient, often paired with clear dosing, and can prove gentler on the stomach than some older drugs. People trying to juggle family, work, and health need options that balance potency with manageable side effects.
Not every story about Benzoylmetronidazole ends quickly. Some folks struggle with allergies or gut upset, and there’re concerns about overuse leading to drug resistance down the line. I’ve watched pharmacists spend extra time explaining how and when to take it, underscoring that incomplete courses mean risks for tougher bugs in the future. We can’t rely only on antibiotics alone—good hygiene, clean water, and preventive education remain as important as the best medicine on the shelf.
Clinicians weigh the evidence before writing a script for Benzoylmetronidazole. It works best with accurate diagnosis and follow-up. Medicine isn’t a one-size-fits-all field. Some patients carry underlying conditions, or have tried other courses that failed. Labs matter, too; up-to-date resistance patterns help doctors predict when this compound still offers the cleanest shot at a cure. In my experience talking with doctors, combining treatment protocols with honest patient conversations produces the safest and most lasting outcomes.
It pays to keep an eye on new research. Ongoing studies look for better ways to deliver these medications, reduce side effects, and predict who benefits most. A healthy respect for these drugs—never using them recklessly, always with a clear diagnosis—keeps them working for years to come. Families, clinicians, and public health workers all play a part in that future.
Benzoylmetronidazole sounds complicated, but at its core, we’re looking at a medicine that doctors reach for when battling certain infections. It’s a prodrug—kind of a “sleeper” compound—that the body transforms into active metronidazole. The whole process means your body can get effective treatment, often with fewer stomach issues. For folks who have struggled with standard metronidazole’s aftertaste or gut reaction, this compound offers a real break.
Doctors prescribe this medication in tablet or capsule form. To get results, I’ve learned from pharmacists that the main thing is swallowing each dose with a full glass of water. Taking it at meals can soothe the digestive tract. Skipping food might stack the odds in favor of nausea or cramps. If you normally forget pills, pairing the dose with lunch or dinner keeps things simple and keeps your routine on track.
Sticking to the schedule matters. Incomplete treatment opens the door for bacteria to fight back, potentially making future infections harder to treat. Even if the symptoms ease off after a few days, don’t put the bottle back in the cabinet until every dose is finished. That discipline pays off—a study published in The Journal of Antimicrobial Chemotherapy showed lower relapse rates among patients who stuck with the full course.
Mixing alcohol with Benzoylmetronidazole brings trouble. The combination triggers reactions like flushing, nausea, and pounding headaches—symptoms nobody wants. Waiting until at least two days after finishing the last pill steers clear of this mess. Even mouthwash or cough syrup with alcohol can cause the same effect. Reading labels makes a difference.
I remember one patient who mentioned feeling dizzy and weak after a double dose by mistake. In cases like that, it helps to stay calm and reach out to a pharmacy, doctor, or even a poison control center. Skipping a dose, on the other hand, doesn’t call for doubling up later—just take the next one as usual.
Common side effects include a metallic taste, mild headache, or upset stomach. If red urine appears, most patients get worried, but it often relates to the way this medicine breaks down in the body and usually doesn’t signal harm. On the other hand, tingling in the hands, sudden rashes, or vision changes ask for immediate medical attention. A 2022 review from the Clinical Infectious Diseases journal stressed how rare but serious allergic reactions can occur.
Trust forms the backbone of treatment. Doctors encourage patients to tell them about allergies, ongoing illnesses, or pregnancy before starting Benzoylmetronidazole. These conversations allow tailored care. Some health centers offer medication counseling—attending these sessions demystifies every instruction, reducing confusion and mistakes.
Organizational tools, such as phone alarms or weekly pill boxes, can keep patients on the right path. In my own experience helping family members manage medications, these tools transformed “Did I take my medicine?” into certainty, not guesswork.
Patients looking for details should lean on reputable medical sites or, best of all, the pharmacist standing behind the counter. That personal connection often reveals details that paperwork or web searches leave out. Sharing experiences, asking questions, and reporting anything unusual build a picture of safety that lasts through the whole course of treatment.
People who struggle with infections often reach for treatment options prescribed by their doctor. Benzoylmetronidazole shows up on those prescriptions at times, especially for infections involving anaerobic bacteria and certain parasites. It’s not as famous as some antibiotics, but it packs a punch where many other drugs fall short.
No medicine acts like a one-way street. Benzoylmetronidazole tackles viruses and bacteria, but it can also bump into organs and systems that don't need the attention. Most people experience mild stomach pain or nausea. I’ve had friends complain about a metallic taste in their mouth during a round of similar drugs, and this one matches that pattern. Some might find headaches or dizziness cropping up, which could make daily tasks feel just a little tougher.
Rashes and itching sometimes follow. Those side effects usually clear up on their own, but it’s easy to overlook the emotional toll small reactions can have. Embarrassing spots or patches do more harm to a teen’s confidence than any pill ever will.
Rare doesn’t mean impossible. Some people run into more serious problems—seizures, numbness, or tingling in the hands and feet hint at nerve involvement. These don’t pop up every day, but they matter. Even doctors can miss the warning signs unless a patient speaks up.
Liver troubles land near the top of the “keep an eye on this” list. Some lab tests will see a bump in liver enzymes. A yellowing of the skin or eyes calls for medical attention as soon as it appears. People with existing liver concerns need to talk to someone with strong experience in these medications.
Mixing Benzoylmetronidazole with alcohol brings trouble. Look up “disulfiram-like reaction” and you'll see stories of flushing, strong nausea, and pounding headaches just from pairing the two. This reaction can hit hard, so skipping alcohol during a course protects both gut and nerves. People on blood thinners or epilepsy medications should check for interactions, as this drug tends to complicate other prescriptions.
Pregnant women and nursing mothers face extra risk. Animal studies can only give part of the picture, and human results haven’t cleared things up enough to wave away concern. Young children also need careful consideration—dose matters more for a child than for an adult, and kidneys process drugs differently through the early years.
Doctors and patients have more success treating infections together through open conversations. If someone feels shaky, spots blood in their stools, or sees odd changes on their skin, reaching out for help beats suffering in silence every time. Pharmacists can walk through expected reactions and flag problems, too.
A growing number of research groups now track patient outcomes and side effects, using real-world data to adjust guidelines. Sharing feedback not only helps the person taking the drug right now but also helps others who might use it in the future. Education, close follow-up, and knowing the warning signs—those tools can cut the risks and support healthier choices.
Safe use of Benzoylmetronidazole depends on treating every patient as an individual. Recognizing that every pill comes with potential benefits and risks gives families confidence. Healthcare decisions supported by shared data, transparency, and honest answers build the trust that keeps people on track, even after the last dose.
Hearing about any medication while expecting brings a wave of worry. With Benzoylmetronidazole, the story is no different. Questions race through an expecting parent’s mind—Is it safe? Will it harm the baby? As someone who’s spent years digging into drug safety, I often tell friends and family that pregnancy is more than just about the individual, it’s about two intertwined lives. Any decision gets an extra layer of importance because the risks are shared.
Benzoylmetronidazole shows up in the same conversation as metronidazole, known for fighting infections caused by bacteria and parasites. The real concern is what these drugs can do during pregnancy and nursing. Medical literature points to mixed findings about metronidazole: some older studies suggested possible risks like cleft lip or low birth weight, but more recent reviews by organizations including the CDC and the American College of Obstetricians and Gynecologists suggest that standard doses do not create major birth defects.
For Benzoylmetronidazole specifically, the research is thin. It doesn’t appear in large studies like metronidazole. Safety data from animal studies and human reports just aren’t there at the same level. Health authorities often draw on patterns of similar drugs, but direct evidence wins every time. This lack of clear research means doctors usually lean toward caution.
Most health decisions during pregnancy and breastfeeding end up involving a close alliance between the patient and their health provider. I’ve seen doctors explain that sometimes the risk of untreated infection outweighs the possible risk from a drug. Infection itself can damage both mother and fetus in subtle or direct ways. I remember hearing about a case where a woman had a stubborn infection and doctors had to weigh the risks. The conversation became less about the medicine itself and more about keeping both patient and child out of danger—always a tough balance.
We live in an age where information is everywhere but trust in sources varies wildly. Pregnant or breastfeeding people turn to government sites, the World Health Organization, or handbooks like Drugs in Pregnancy and Lactation. No one wants to take chances, and that’s understandable, but delay in treating an infection can make things worse.
Whatever goes into a new parent’s body has a shot at reaching their child through breast milk. With metronidazole, studies have found traces in breast milk, though usually at low levels. Experts advise caution. Some recommend discarding breast milk for a day if a single high dose is needed. In practice, these choices might mean temporary bottle feeding to play it safe. Without concrete Benzoylmetronidazole data, most will echo this advice or vote to use a different medication.
A clearer road demands more research and easier access to trustworthy resources. Better pregnancy registries that track real-life medication exposure could fill knowledge gaps. Doctors and pharmacists can help by staying up to date and guiding patients through risks and benefits. For anyone in this position, bringing every medication—prescription or over-the-counter—to prenatal visits is a good habit. Staying open with providers ensures better safety and peace of mind for both parent and child.
Doctors and pharmacists keep an eye on how any medicine plays with others because a mix-up complicates recovery and can push patients into emergency rooms. Benzoylmetronidazole isn’t as familiar as paracetamol or ibuprofen, yet there’s growing curiosity around how it behaves, especially paired with meds already piling up on cabinet shelves. This concern isn’t just another medical “what if”—I’ve watched friends swap pills for acne, infections, or stomach issues, worrying if their evening heart medication or the cup of turmeric tea will backfire from a new prescription.
Benzoylmetronidazole comes from the same family as metronidazole, a name hospital workers and people with tough infections recognize. Metronidazole itself interacts with alcohol (delivering some nasty stomach churns and headaches) and meddles with blood thinners like warfarin, which could ramp up the risk of internal bleeding. Most doctors flag those risks clearly, scribbling reminders for patients not to toast their antibiotics with a beer after dinner.
Benzoylmetronidazole hasn’t stacked up as much clinical documentation, but its roots suggest caution. A lot of drugs in this class compete for liver enzymes, pushing other meds up or down in strength—sometimes silently, until the blood test results or sudden unexpected symptoms. For example, antiepileptics and blood thinners pop up often as problem partners. My experience sitting in on a busy urban clinic’s weekly review showed that even rare interactions could trigger headaches for everyone involved: patients who just wanted relief, and providers juggling limited information about new compounds.
Health workers deal with patients, not petri dishes. Picture an older adult on multiple drugs for blood pressure, diabetes, or chronic infections thrown into the mix with Benzoylmetronidazole. Overlapping side effects like nausea or dizziness do more than inconvenience—they can drive people to skip doses, or worse, wind up in hospital beds with drug-induced falls or bleeding. My neighbor’s mother, juggling prescriptions, skipped important antibiotics out of anxiety from unclear pharmacy advice. She landed in the ER with an infection that could have been handled early with better guidance.
Clear advice saves lives. Doctors and pharmacists need full medication lists—over-the-counter, herbal, and supplements. Patients who keep an up-to-date list or snap a photo of their bottles have dodged confusion. Pharmacists who check interaction databases before filling that unfamiliar blue-and-white capsule spot allergies and red flags faster. Tech helps, but personal reminders—like that sticky note on the medicine cabinet that says, “No grapefruit!” or an app alarm—make guidance actionable outside clinics.
Drug companies need to run proper studies on Benzoylmetronidazole interactions, then share both the numbers and the human stories. The faster these details reach frontline primary care and pharmacy teams, the safer prescriptions get. This shift matters more now, with new drugs landing every year and older generations managing long lists of medications. People deserve more than guesswork.
| Names | |
| Preferred IUPAC name | 1-(2-Hydroxyethyl)-2-methyl-5-nitro-1H-imidazol-3-ium-3-yl benzoate |
| Other names |
Phthalidyl Metronidazole Phthalidylimidazole |
| Pronunciation | /ˌbɛn.zɔɪl.mɛˌtrɒ.nɪˈdaɪ.zɒl/ |
| Identifiers | |
| CAS Number | [13182-89-3] |
| Beilstein Reference | Beilstein Reference 606116 |
| ChEBI | CHEBI:60913 |
| ChEMBL | CHEMBL2106361 |
| ChemSpider | 5344041 |
| DrugBank | DB13627 |
| ECHA InfoCard | 100.180.935 |
| EC Number | 248-047-7 |
| Gmelin Reference | 84258 |
| KEGG | C13818 |
| MeSH | D001548 |
| PubChem CID | 63554 |
| RTECS number | SY8579000 |
| UNII | 2X38XN7P9D |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID2021806 |
| Properties | |
| Chemical formula | C13H13N3O4 |
| Molar mass | 309.28 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.367 g/cm3 |
| Solubility in water | Slightly soluble in water |
| log P | 1.53 |
| Vapor pressure | 1.10E-8 mmHg |
| Acidity (pKa) | 14.12 |
| Basicity (pKb) | 2.17 |
| Magnetic susceptibility (χ) | -64.2·10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.657 |
| Dipole moment | 4.67 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 496.3 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -173.4 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -5998 kJ/mol |
| Pharmacology | |
| ATC code | J01XD03 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. May cause respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | MF: C13H12N3O3 InChI: InChI=1S/C13H12N3O3/c1-19-11-4-2-3-9(7-11)12(17)15-10-5-6-14-8-16(10)13(15)18/h2-8H,1H3 InChIKey: UVRFRMZKPFQJRM-UHFFFAOYSA-N SMILES: COc1cccc(c1)C(=O)N2C=NC=C2[N+](=O)[O-] |
| Signal word | Warning |
| Hazard statements | H315: Causes skin irritation. H319: Causes serious eye irritation. H335: May cause respiratory irritation. |
| Precautionary statements | P264, P270, P273, P301+P312, P330, P501 |
| NFPA 704 (fire diamond) | Health: 2, Flammability: 1, Instability: 0, Special: - |
| Flash point | Flash point: 290.9 °C |
| Lethal dose or concentration | LD50 (rat, oral): 3600 mg/kg |
| LD50 (median dose) | LD50 (median dose) of Benzoylmetronidazole: "3850 mg/kg (oral, mouse) |
| NIOSH | RS0873330 |
| PEL (Permissible) | PEL (Permissible Exposure Limit) for Benzoylmetronidazole: Not established |
| REL (Recommended) | Metronidazole |
| Related compounds | |
| Related compounds |
Metronidazole Benzoyl peroxide Benznidazole Ornidazole Tinidazole |
